Concerns regarding tablet splitting: a systematic review

BJGP Open. 2022 Sep 28;6(3):BJGPO.2022.0001. doi: 10.3399/BJGPO.2022.0001. Print 2022 Sep.

Abstract

Background: Tablet splitting can provide dose flexibility and cost savings; however, pharmaceutical representatives typically discourage the practice.

Aim: To identify and summarise all published concerns related to tablet splitting and to present the experimental evidence that investigates those concerns.

Design & setting: Systematic review and qualitative synthesis of tablet-splitting concerns and evidence.

Method: Medline and EMBASE databases were searched over all years of publication for articles in English discussing the splitting of tablets. Eligible articles included original research, narrative reviews, systematic reviews, and expert opinion.

Results: After removing duplicates, 1837 potentially relevant articles underwent dual review, whereupon 1612 articles were excluded based on title and abstract. After examination of 225 full texts, 138 articles were included (one systematic review, four narrative reviews, 101 original research articles, and 32 opinion articles). The described concerns included difficulty breaking tablets, loss of mass, weight variability, chemical instability, overly rapid dosing if sustained-release medications are split, non-compliance, and patient confusion resulting in medication errors. No substantive evidence was found to support concerns regarding loss of mass, weight variability, chemical instability, or non-compliance. Evidence does support some older adults struggling to split tablets without tablet splitters, and the inappropriateness of splitting sustained-release preparations, given the potential for alteration of the rate of drug release for some products.

Conclusion: With the exception of sustained-release tablets, which should not be split, and excepting those older people who may struggle to split tablets based on physical limitations, there is little evidence to support tablet-splitting concerns.

Keywords: cost savings; delayed-action preparations; dose-reduction; geriatric prescribing; medication errors; pill-splitting; tablets.